Huntington’s Disease News and Research

RSS

Huntington Hospital uses Voalte One system to help nurses improve communication at point-of-care

Nationwide, nurse workloads have increased due to higher patient acuity, increased documentation requirements and shortages of staff. Today's nurse finds it more difficult to manage the multiple demands of patients, families and other members of the healthcare team. Put simply, nurses frequently lack the time to do what they joined the profession to do -- provide quality patient care.

19 Jan 2010

Down syndrome and Alzheimer's disease are the same

Nearly 20 years ago Huntington Potter kicked up a storm of controversy with the idea that Down syndrome and Alzheimer's were the same disease. Now the evidence is in: He was right.

18 Jan 2010

Metabolon awarded US Patent for ‘metabolomics methods’

Metabolon, Inc., the leader in global metabolism through biomarker discovery and analysis, today announced that it was awarded US Patent 7,635,556 “Methods for Drug Discovery, Disease Treatment and Diagnosis Using Metabolomics” by the United States Patent and Trademark Office on December 22, 2009.

18 Jan 2010

FDA approves TCA-CT's adult stem cell protocol for conducting Phase I clinical trials in ALS

TCA Cellular Therapy, LLC (TCA-CT) announced today that the U.S. Food and Drug Administration (FDA) has approved its adult stem cell protocol to conduct Phase I clinical trials to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease).

18 Jan 2010

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

Thanks in part to more than a decade of preclinical work by Dartmouth researchers, a Japanese biopharmaceutical firm is preparing to develop and market throughout Asia a drug for the treatment of chronic kidney disease (CKD).

18 Jan 2010

AMGA reports significant growth in 2009; 2010 paves way for another successful year

The American Medical Group Association (AMGA) announced significant growth in 2009, during which it added 40 new member groups, representing more than 9,700 physicians treating 11 million patients.

17 Jan 2010

Genomic and Personalized Medicine Conference in USA

Elsevier announced today the Genomic and Personalized Medicine Conference in Arlington, VA, USA from May 16-18, 2010, which is, supported by The Lancet and organized in association with the book 'Genomic and Personalized Medicine.

13 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Findings open up significant possibilities for developing micro-screening devices for drug discovery

A Nobel-winning process for testing new drugs to treat diseases such as Huntington's, Parkinson's, and muscular dystrophy is getting an electrical charge.

6 Jan 2010

Test tube experiments show slight changes in protein chemistry can eliminate Huntington's disease in mice

In Huntington's disease, a mutated protein in the body becomes toxic to brain cells. Recent studies have demonstrated that a small region adjacent to the mutated segment plays a major role in the toxicity. Two new studies supported by the National Institutes of Health show that very slight changes to this region can eliminate signs of Huntington's disease in mice.

28 Dec 2009

Key molecular switch linked to HD identified

Scientists have identified a key molecular switch that may drive the onset of Huntington's disease (HD), an incurable neurodegenerative disorder that leads to severe disruptions in muscle coordination and cognitive function. The research, published by Cell Press in the December 24 issue of the journal Neuron, enhances the understanding of HD pathogenesis and may direct new strategies for treating this devastating brain disease.

24 Dec 2009

IKK phosphorylate: A double-edged sword in Huntington's disease

The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, led by researchers from the University of California, Irvine, will be published online December 21 in the Journal of Cell Biology (www.jcb.org).

22 Dec 2009

DR Systems announces eight new contracts with U.S. healthcare facilities

DR Systems, makers of the Unity™ RIS/PACS, today announced eight new contracts with healthcare facilities across the U.S. The contracts total more than $2.37 million. The eight facilities are:

22 Dec 2009

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

Diet rich in omega-3 fatty acids linked to improved nervous-system function

The omega-3 essential fatty acids commonly found in fatty fish and algae help animals avoid sensory overload, according to research published by the American Psychological Association.

17 Dec 2009

University of Florida obtains stimulus grant to establish ataxia consortium

University of Florida neurologists are trying to change that with the help of a $1 million Challenge grant from the National Institute of Neurological Disorders and Stroke to establish a nationwide network of physician-scientists with expertise in clinical ataxia research.

16 Dec 2009

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

The Cedars-Sinai Regenerative Medicine Institute is to provide stem cells to a five-member National Institutes of Health consortium of researchers for development of potential therapies to treat Huntington's disease.

8 Dec 2009

Combination of green tea and DAPH-12 chemicals may help prevent brain disorders

Scientists at Boston Biomedical Research Institute (BBRI) and the University of Pennsylvania have found that combining two chemicals, one of which is the green tea component EGCG, can prevent and destroy a variety of protein structures known as amyloids. Amyloids are the primary culprits in fatal brain disorders such as Alzheimer's, Huntington's, and Parkinson's diseases.

4 Dec 2009

Huntington Memorial Hospital's stroke program receives Gold Seal of Approval

Huntington Memorial Hospital's stroke program has received the Gold Seal of Approval from the Joint Commission, designating the hospital a primary stroke center. This means Huntington will join the network of "approved stroke center" hospitals throughout Los Angeles County.

3 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

Huntington’s Disease News and Research

Huntington Hospital uses Voalte One system to help nurses improve communication at point-of-care

Down syndrome and Alzheimer's disease are the same

Metabolon awarded US Patent for ‘metabolomics methods’

FDA approves TCA-CT's adult stem cell protocol for conducting Phase I clinical trials in ALS

Dartmouth researchers to develop and market a drug throughout Asia for treatment of CKD

AMGA reports significant growth in 2009; 2010 paves way for another successful year

Genomic and Personalized Medicine Conference in USA

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Findings open up significant possibilities for developing micro-screening devices for drug discovery

Test tube experiments show slight changes in protein chemistry can eliminate Huntington's disease in mice

Key molecular switch linked to HD identified

IKK phosphorylate: A double-edged sword in Huntington's disease

DR Systems announces eight new contracts with U.S. healthcare facilities

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Diet rich in omega-3 fatty acids linked to improved nervous-system function

University of Florida obtains stimulus grant to establish ataxia consortium

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

Combination of green tea and DAPH-12 chemicals may help prevent brain disorders

Huntington Memorial Hospital's stroke program receives Gold Seal of Approval

FDA approves revised clinical trial protocol for CytRx' arimoclomol

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News